JO3773B1 - معدلات p2x7 - Google Patents

معدلات p2x7

Info

Publication number
JO3773B1
JO3773B1 JOP/2014/0094A JOP20140094A JO3773B1 JO 3773 B1 JO3773 B1 JO 3773B1 JO P20140094 A JOP20140094 A JO P20140094A JO 3773 B1 JO3773 B1 JO 3773B1
Authority
JO
Jordan
Prior art keywords
iib
iia
formulas
compounds
rates
Prior art date
Application number
JOP/2014/0094A
Other languages
English (en)
Inventor
Soyode-Johnson Akinola
R Coate Heather
C Rech Jason
A Letavic Michael
C Chrovian Christa
L Wall Jessica
F Gelin Christine
Stenne Brice
De Angelisz Meri
D Allison Brett
S Mani Neelakandha
Jesus Alcazar Vaca Manuel
Ignacio Andres Gil Jose
M Swanson Devin
A Dvorak Curt
Deng Xiaohu
M Savall Brad
T Liang Jimmy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3773B1 publication Critical patent/JO3773B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)

Abstract

يتعلق هذا الاختراع بمركبات الصيغة (I، Ia، IIa و IIb): يتعلق الاختراع أيضاً بتركيبات صيدلية تشتمل على مركبات الصيغة (I، Ia، IIa و IIb). وتكون طرق عمل واستخدام مركبات الصيغة (I، Ia، IIa و IIb) أيضاً داخل مجال الاختراع.
JOP/2014/0094A 2013-03-14 2014-03-12 معدلات p2x7 JO3773B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361786260P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
JO3773B1 true JO3773B1 (ar) 2021-01-31

Family

ID=50543353

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0094A JO3773B1 (ar) 2013-03-14 2014-03-12 معدلات p2x7

Country Status (33)

Country Link
US (8) US10112937B2 (ar)
EP (3) EP3239151B1 (ar)
JP (1) JP6293861B2 (ar)
KR (5) KR102500076B1 (ar)
CN (2) CN110003200B (ar)
AR (2) AR095530A1 (ar)
AU (5) AU2014239291B2 (ar)
BR (1) BR112015023142B1 (ar)
CA (1) CA2906085C (ar)
CL (3) CL2015002655A1 (ar)
CY (1) CY1119110T1 (ar)
DK (2) DK3239151T3 (ar)
EA (1) EA028816B1 (ar)
ES (2) ES2704024T3 (ar)
HR (1) HRP20171168T4 (ar)
HU (1) HUE032877T2 (ar)
IL (1) IL240880B (ar)
JO (1) JO3773B1 (ar)
LT (1) LT2970267T (ar)
ME (1) ME02802B (ar)
MX (2) MX364796B (ar)
PH (1) PH12015501930A1 (ar)
PL (1) PL2970267T6 (ar)
PT (2) PT3239151T (ar)
RS (1) RS56315B2 (ar)
SG (2) SG10201700889PA (ar)
SI (1) SI2970267T1 (ar)
SM (1) SMT201700352T1 (ar)
TW (2) TWI599567B (ar)
UA (1) UA116467C2 (ar)
UY (3) UY35469A (ar)
WO (1) WO2014152604A1 (ar)
ZA (1) ZA201507627B (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
DK2970283T3 (da) 2013-03-14 2021-01-25 Boehringer Ingelheim Int Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015172196A1 (en) * 2014-05-13 2015-11-19 Monash University Heterocyclic compounds and use of same
JP6625616B2 (ja) 2014-09-12 2019-12-25 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節n−アシル−トリアゾロピラジン
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
EP3191487B1 (en) 2014-09-12 2019-08-07 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
EP3287443B1 (en) 2015-04-24 2021-10-27 Shionogi & Co., Ltd 6-membered heterocyclic derivative and pharmaceutical composition comprising same
AU2016304182B2 (en) * 2015-07-31 2020-08-27 Merck Patent Gmbh Bicyclic heterocyclic derivatives
US11066409B2 (en) 2016-10-17 2021-07-20 Shionogi & Co., Ltd. Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same
ES2862405T3 (es) * 2016-12-02 2021-10-07 Fraunhofer Ges Forschung Inhibidores de glutaminil ciclasas bacterianas y uso de los mismos en el tratamiento de periodontitis
DK3609868T3 (da) * 2017-03-13 2023-11-27 Raqualia Pharma Inc Tetrahydroquinolinderivater som P2X7-receptorantagonister
WO2019099509A1 (en) * 2017-11-14 2019-05-23 Second Genome, Inc. Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
WO2019152374A1 (en) * 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MA53219B1 (fr) 2018-08-13 2024-09-30 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
MX2021003737A (es) * 2018-09-28 2021-05-14 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipasa.
CA3111309A1 (en) * 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CN109400605A (zh) * 2018-11-27 2019-03-01 复旦大学附属中山医院 一种p2x7受体显像剂及其制备方法
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
MX2022003819A (es) * 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.
BR112022013849A2 (pt) * 2020-01-13 2022-09-13 Aptabio Therapeutics Inc Novo derivado de pirazol
KR20220157999A (ko) * 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
CN115894452B (zh) * 2021-08-18 2024-04-09 四川大学 一种p2x7受体抑制剂
WO2025091145A1 (zh) * 2023-10-30 2025-05-08 复旦大学 糖尿病肾病诊断药物及应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA2093125C (en) 1990-10-02 2003-12-16 Warner-Lambert Company Angiotensin ii antagonists
US8933236B2 (en) 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
US20060100233A1 (en) * 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
FR2857363B1 (fr) * 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
AU2005277283A1 (en) 2004-08-23 2006-03-02 Merck Sharp & Dohme Corp. Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20080146612A1 (en) 2005-01-27 2008-06-19 Astrazeneca Ab Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
AU2008269177A1 (en) 2007-06-21 2008-12-31 Schering Corporation Polycyclic Guanine Derivatives and use thereof
NZ582056A (en) * 2007-08-10 2012-08-31 Lundbeck & Co As H Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
US8431704B2 (en) 2008-04-22 2013-04-30 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted P2X7 antagonists
JP5063815B2 (ja) * 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP5654001B2 (ja) * 2009-04-29 2015-01-14 グラクソ グループ リミテッドGlaxo Group Limited P2X7調節因子としての5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[4,3−a]ピラジン誘導体
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
US9062044B2 (en) 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
JP5822911B2 (ja) 2010-04-02 2015-11-25 ユーロスクリーン エス.エー. 新規のnk−3受容体選択的アンタゴニスト化合物、医薬組成物、及びnk−3受容体媒介疾患における使用方法
US20110252717A1 (en) 2010-04-16 2011-10-20 Graf Fernandez Rodrigo Foldable structures for a construction
EP2619204A4 (en) 2010-09-21 2014-08-27 Merck Sharp & Dohme TRIAZOLOPYRAZINONE AS P2X7 RECEPTOR ANTAGONISTS
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US9273947B2 (en) 2012-02-07 2016-03-01 Lg Innotek Co., Ltd. Sensing magnet apparatus for motor
JP5205547B1 (ja) 2012-04-20 2013-06-05 株式会社ノイズ研究所 放射信号可視化装置
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
PE20150886A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
ME02794B (me) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
BR112015009942A2 (pt) 2012-11-01 2017-07-11 Incyte Corp derivados de tiofeno fundidos tricíclicos como inibidores de jak
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
EA028774B1 (ru) 2012-12-21 2017-12-29 Квонтисел Фармасьютикалс, Инк. Ингибиторы гистондеметилазы
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
US9676748B2 (en) 2012-12-21 2017-06-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20151274A1 (es) 2013-02-08 2015-09-12 Celgene Avilomics Res Inc Inhibidores de erk y sus usos
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
HUE047681T2 (hu) 2013-03-06 2020-05-28 Janssen Pharmaceutica Nv A hisztamin H4 receptor benzimidazol-2-il-pirimidin modulátorai
PE20151593A1 (es) 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
DK2970283T3 (da) 2013-03-14 2021-01-25 Boehringer Ingelheim Int Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
MA38461B1 (fr) 2013-03-14 2021-10-29 Curadev Pharma Private Ltd Inhibiteurs de la voie de la kynurénine
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
SG11201506245QA (en) 2013-03-14 2015-09-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP6275242B2 (ja) 2013-03-29 2018-02-07 オゲダ エス.エー. 選択的NK−3受容体拮抗薬としての新規なN−アシル−(3位置換)−(8−メチル)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、その医薬組成物、NK−3受容体媒介性障害で使用する方法
JP6625616B2 (ja) 2014-09-12 2019-12-25 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節n−アシル−トリアゾロピラジン
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
MX2021003737A (es) 2018-09-28 2021-05-14 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipasa.
MX2022003819A (es) 2019-09-30 2022-05-11 Janssen Pharmaceutica Nv Ligandos de pet de mgl radiomarcados.

Also Published As

Publication number Publication date
HK1218541A1 (en) 2017-02-24
TWI599567B (zh) 2017-09-21
CN110003200A (zh) 2019-07-12
UY39887A (es) 2023-06-15
MX2022011795A (es) 2022-10-10
EP3239151A1 (en) 2017-11-01
MX364796B (es) 2019-05-07
CA2906085A1 (en) 2014-09-25
ME02802B (me) 2018-01-20
SG10201700889PA (en) 2017-03-30
HRP20171168T4 (hr) 2018-09-21
AU2019203186B2 (en) 2021-06-24
US20140275015A1 (en) 2014-09-18
WO2014152604A1 (en) 2014-09-25
US20240116930A1 (en) 2024-04-11
HUE032877T2 (hu) 2017-11-28
DK3239151T3 (en) 2019-01-21
LT2970267T (lt) 2017-07-10
CL2017002609A1 (es) 2018-03-16
UY39888A (es) 2022-09-30
SMT201700352T1 (it) 2017-09-07
BR112015023142A2 (pt) 2017-07-18
IL240880B (en) 2019-05-30
KR20250004140A (ko) 2025-01-07
CL2015002655A1 (es) 2016-03-04
AR123048A2 (es) 2022-10-26
DK2970267T3 (en) 2017-07-24
UY35469A (es) 2014-09-30
MX2015012095A (es) 2016-05-10
US9464084B2 (en) 2016-10-11
US20200325138A1 (en) 2020-10-15
US10112937B2 (en) 2018-10-30
EP2970267B3 (en) 2018-05-30
SG11201507259UA (en) 2015-10-29
KR102516711B1 (ko) 2023-03-30
CN105209464A (zh) 2015-12-30
PL2970267T3 (pl) 2017-11-30
ES2704024T3 (es) 2019-03-13
ES2635318T3 (es) 2017-10-03
SI2970267T1 (sl) 2017-08-31
CL2017002610A1 (es) 2018-03-16
AR095530A1 (es) 2015-10-21
KR20220044376A (ko) 2022-04-07
EA028816B1 (ru) 2018-01-31
AU2021236451A1 (en) 2021-10-14
CN110003200B (zh) 2021-11-26
US20160039809A1 (en) 2016-02-11
AU2017206153B2 (en) 2019-02-14
US9066946B2 (en) 2015-06-30
UA116467C2 (uk) 2018-03-26
BR112015023142A8 (pt) 2019-12-03
EP2970267B1 (en) 2017-05-24
EA201591748A1 (ru) 2016-02-29
CY1119110T1 (el) 2018-02-14
US11820770B2 (en) 2023-11-21
AU2021236451B2 (en) 2024-02-01
EP3239151B1 (en) 2018-11-07
KR20230049754A (ko) 2023-04-13
US10150765B2 (en) 2018-12-11
KR20150127723A (ko) 2015-11-17
ES2635318T7 (es) 2018-09-11
NZ711699A (en) 2020-10-30
US12247027B2 (en) 2025-03-11
RS56315B1 (sr) 2017-12-29
ZA201507627B (en) 2023-11-29
US10703749B2 (en) 2020-07-07
HRP20171168T1 (hr) 2017-10-06
IL240880A0 (en) 2015-10-29
EP2970267A1 (en) 2016-01-20
AU2024201709A1 (en) 2024-04-04
CA2906085C (en) 2023-01-03
US20160376271A1 (en) 2016-12-29
DK2970267T6 (en) 2018-09-03
US20150322062A1 (en) 2015-11-12
PT3239151T (pt) 2019-01-28
AU2014239291B2 (en) 2017-06-15
TW201740940A (zh) 2017-12-01
EP3495365A1 (en) 2019-06-12
TWI644671B (zh) 2018-12-21
KR20210132743A (ko) 2021-11-04
KR102500076B1 (ko) 2023-02-14
AU2017206153A1 (en) 2017-08-17
BR112015023142B1 (pt) 2023-05-02
KR102319857B1 (ko) 2021-11-01
US20190092770A1 (en) 2019-03-28
JP2016515135A (ja) 2016-05-26
PL2970267T6 (pl) 2018-11-30
US11225478B2 (en) 2022-01-18
PT2970267T (pt) 2017-08-25
AU2014239291A1 (en) 2015-09-17
AU2019203186A1 (en) 2019-05-30
TW201446762A (zh) 2014-12-16
CN105209464B (zh) 2019-01-01
RS56315B2 (sr) 2018-08-31
US20220213095A1 (en) 2022-07-07
PH12015501930A1 (en) 2016-01-04
JP6293861B2 (ja) 2018-03-14

Similar Documents

Publication Publication Date Title
JO3773B1 (ar) معدلات p2x7
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
EA201591527A1 (ru) Новые производные пиридина
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201590534A1 (ru) Новые бициклические производные
SV2014004770A (es) Nuevos derivados de pirrol, su procedimiento de preparación y los composiciones farmacéuticas que los contienen
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
MX381719B (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
EA201591064A1 (ru) Новые производные пиридина
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
UA116239C2 (uk) Нові похідні піридину
MX364069B (es) Moduladores de la proteína activadora de 5-lipoxigenasa.
JO3793B1 (ar) مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201500931A1 (ru) Производные пиридин-4-ила
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
HK1221645A1 (zh) Vmat2的苯并喹啉抑制剂